Covid-19 Vaccine Clinical Trial
Official title:
PROmotion of COvid-19 VA(X)Ccination in the Emergency Department - PROCOVAXED
The goal of this research is to increase COVID-19 vaccine acceptance and uptake in vulnerable populations whose primary (and often only) health care access occurs in emergency departments (ED Usual Source of Care Patients). Toward this goal, the investigators will conduct one on one interviews and focus groups with ED Usual Source of Care Patients and community partners and produce trusted messaging informational platforms (PROmotion of COvid-19 VA(X)ccination in the Emergency Department - PROCOVAXED) that will address barriers to COVID-19 vaccination, especially vaccine hesitancy. The investigators will then conduct a cluster-randomized, controlled trial of PROCOVAXED platforms in six EDs to determine whether their implementation is associated with greater COVID-19 vaccine acceptance and uptake in ED Usual Source of Care Patients.
The investigator's preliminary work research at 15 ED sites across the US indicates that ED Usual Source of Care patients have particular health care access barriers, needs, and perceptions about vaccines (vaccine hesitancy) that require specific review beyond traditional (non-ED user) community engagement techniques. To gain insight about messaging that effectively addresses these barriers, needs, and perceptions, the investigators will conduct one on one interviews and focus group meetings with ED Usual Source of Care Patients and community partners. At five safety net EDs (Zuckerberg San Francisco General, Thomas Jefferson University Hospital [Philadelphia], Methodist Hospital [Philadelphia], Harborview Medical Center [Seattle], and Duke University Medical Center [Durham, NC], the investigators will conduct a cluster-randomized, controlled trial of implementation of PROCOVAXED platforms, with COVID-19 and influenza vaccine acceptance rates on post-intervention ED surveys as the primary outcomes. Hypothesis: Implementation of PROCOVAXED platforms in EDs will be associated with increased acceptance of COVID-19 vaccines in ED patients. One month after subjects' index ED visit enrollment in our PROCOVAXED implementation trial, the investigators will conduct electronic health record review and phone follow-up surveys to determine ED patient uptake (receipt) of COVID-19 vaccines. Hypothesis: Implementation of PROCOVAXED platforms in EDs will be associated with greater COVID-19 vaccine uptake in ED patients. The investigators will conduct a cluster-randomized, controlled trial (RCT) of implementation of our PROCOVAXED platforms in 5 high-volume, safety net hospital EDs, testing two hypotheses that implementation of PROCOVAXED platforms will be associated with increased acceptance and uptake of COVID-19 vaccines in ED Usual Source of Care Patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05049226 -
Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine
|
Phase 2 | |
Recruiting |
NCT05998824 -
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease
|
N/A | |
Recruiting |
NCT05097053 -
A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19
|
Phase 4 | |
Active, not recruiting |
NCT05463419 -
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05293223 -
Phase IIB Study of Recombinant Novel Coronavirus Vaccine
|
Phase 2 | |
Completed |
NCT04691947 -
Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC
|
Phase 1 | |
Completed |
NCT05288231 -
Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand
|
||
Completed |
NCT04546841 -
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults
|
Phase 1 | |
Recruiting |
NCT04963790 -
Enabling Family Physicians to Reduce Vaccine Hesitancy and Increase Covid-19 Vaccine Uptake
|
N/A | |
Completed |
NCT05216601 -
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19
|
Phase 1 | |
Completed |
NCT04566276 -
ChulaCov19 Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04915820 -
Iron and COVID-19 Vaccine Response
|
N/A | |
Completed |
NCT05268679 -
Covid-19 Vaccine Response in Heart Transplant Recipients
|
||
Completed |
NCT04898946 -
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
|
||
Recruiting |
NCT05869968 -
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
|
||
Active, not recruiting |
NCT05197712 -
Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease
|
Phase 1 | |
Recruiting |
NCT05553743 -
Researchers at UC San Diego Are Learning About the Benefits of Human Milk and How it Influences Infant and Child Health
|
||
Active, not recruiting |
NCT05188469 -
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
|
Phase 1/Phase 2 | |
Completed |
NCT04764422 -
Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand
|
Phase 1/Phase 2 | |
Recruiting |
NCT04838080 -
Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo
|
Phase 1 |